Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Starting SGLT2 inhibitors led to a lower risk of eGFR ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

ORLANDO -- Adding a low dose of an SGLT2 inhibitor to insulin improved renal function and glycemic control in adolescents with type 1 diabetes (T1D), the late-breaking ATTEMPT trial found. In the ...

The researchers assessed the therapy's effects on kidney function over time and evaluated its effects on heart failure outcomes in relation to kidney function. It is especially important to understand ...

Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with type 2 diabetes.